Neurotensin receptor 1-biased ligand attenuates neurotensin-mediated excitation of ventral tegmental area dopamine neurons and dopamine release in the nucleus accumbens

[1]  Taiju Amano,et al.  Diverse intracellular signaling pathways mediate the effects of neurotensin on the excitability of type II neurons in the rat dorsolateral bed nucleus of the stria terminalis. , 2021, Journal of pharmacological sciences.

[2]  S. Lei,et al.  Ionic and signaling mechanisms involved in neurotensin-mediated excitation of central amygdala neurons , 2021, Neuropharmacology.

[3]  N. Urs,et al.  Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders , 2021, CNS Drugs.

[4]  Z. Freyberg,et al.  Roles of dopamine and glutamate co‐release in the nucleus accumbens in mediating the actions of drugs of abuse , 2020, The FEBS journal.

[5]  W. Wetsel,et al.  β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors , 2020, Cell.

[6]  María Luisa Torruella-Suárez,et al.  Neurotensin in reward processes , 2020, Neuropharmacology.

[7]  Hideaki E. Kato,et al.  Structure of the Neurotensin Receptor 1 in complex with β-arrestin 1 , 2020, Nature.

[8]  M. Jackson,et al.  Discovery of b-Arrestin Biased, Orally Bioavailable and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators. , 2019, Journal of medicinal chemistry.

[9]  G. Leinninger,et al.  Mapping the populations of neurotensin neurons in the male mouse brain , 2019, Neuropeptides.

[10]  M. Beckstead,et al.  Depression of substantia nigra dopamine transmission is driven by retrograde neurotensin release and is enhanced by methamphetamine self-administration , 2019, bioRxiv.

[11]  M. Beckstead,et al.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission , 2019, The European journal of neuroscience.

[12]  Brian R. Lee,et al.  Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method , 2018, Journal of visualized experiments : JoVE.

[13]  Hannah M. Batchelor,et al.  Determination of neurotensin projections to the ventral tegmental area in mice , 2018, Neuropeptides.

[14]  G. Leinninger,et al.  Identification of Neurotensin Receptor Expressing Cells in the Ventral Tegmental Area across the Lifespan , 2018, eNeuro.

[15]  Bing Huang,et al.  β-Arrestin–biased β-adrenergic signaling promotes extinction learning of cocaine reward memory , 2018, Science Signaling.

[16]  V. Alvarez,et al.  Distinctive Modulation of Dopamine Release in the Nucleus Accumbens Shell Mediated by Dopamine and Acetylcholine Receptors , 2017, The Journal of Neuroscience.

[17]  Hannah M. Batchelor,et al.  Neurotensin Receptor-1 Identifies a Subset of Ventral Tegmental Dopamine Neurons that Coordinates Energy Balance. , 2017, Cell reports.

[18]  M. Beckstead,et al.  Systemic PD149163, a neurotensin receptor 1 agonist, decreases methamphetamine self-administration in DBA/2J mice without causing excessive sedation , 2017, PloS one.

[19]  Philippe Sarret,et al.  The signaling signature of the neurotensin type 1 receptor with endogenous ligands , 2017, European journal of pharmacology.

[20]  Kirsten A. Porter-Stransky,et al.  Arresting the Development of Addiction: The Role of β-Arrestin 2 in Drug Abuse , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[21]  C. Lüscher.  The Emergence of a Circuit Model for Addiction. , 2016, Annual review of neuroscience.

[22]  P. Kalivas,et al.  The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis , 2016, Pharmacological Reviews.

[23]  R. Rodriguiz,et al.  ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse. , 2016, ACS chemical biology.

[24]  S. Rajagopal,et al.  The β-Arrestins: Multifunctional Regulators of G Protein-coupled Receptors* , 2016, The Journal of Biological Chemistry.

[25]  K. Fuxe,et al.  Neurotensin: A role in substance use disorder? , 2016, Journal of psychopharmacology.

[26]  M. D'Souza,et al.  Glutamatergic transmission in drug reward: implications for drug addiction , 2015, Front. Neurosci..

[27]  C. P. Ford,et al.  Neurotensin Induces Presynaptic Depression of D2 Dopamine Autoreceptor-Mediated Neurotransmission in Midbrain Dopaminergic Neurons , 2015, The Journal of Neuroscience.

[28]  A. G. Roseberry,et al.  Neurotensin inhibits both dopamine- and GABA-mediated inhibition of ventral tegmental area dopamine neurons. , 2015, Journal of neurophysiology.

[29]  O. Mabrouk,et al.  Ventral tegmental area neurotensin signaling links the lateral hypothalamus to locomotor activity and striatal dopamine efflux in male mice. , 2015, Endocrinology.

[30]  C. P. Ford.  The role of D2-autoreceptors in regulating dopamine neuron activity and transmission , 2014, Neuroscience.

[31]  E. Richelson,et al.  Elucidating the Role of Neurotensin in the Pathophysiology and Management of Major Mental Disorders , 2014, Behavioral sciences.

[32]  E. Richelson,et al.  Diverse Roles of Neurotensin Agonists in the Central Nervous System , 2013, Front. Endocrinol..

[33]  Patrick E. Rothwell,et al.  Integrating synaptic plasticity and striatal circuit function in addiction , 2012, Current Opinion in Neurobiology.

[34]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[35]  R. Lefkowitz,et al.  Therapeutic potential of β-arrestin- and G protein-biased agonists. , 2011, Trends in molecular medicine.

[36]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[37]  L. Trudeau,et al.  Neurotensin Triggers Dopamine D2 Receptor Desensitization through a Protein Kinase C and β-Arrestin1-dependent Mechanism* , 2011, The Journal of Biological Chemistry.

[38]  L. Trudeau,et al.  Presynaptic action of neurotensin on dopamine release through inhibition of D2 receptor function , 2009, BMC Neuroscience.

[39]  C. Iitaka,et al.  Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. , 2009, Current opinion in pharmacology.

[40]  K. Fuxe,et al.  Neurotensin receptors as modulators of glutamatergic transmission , 2008, Brain Research Reviews.

[41]  K. Fuxe,et al.  Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides , 2007, Brain Research Reviews.

[42]  H. Okano,et al.  Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons , 2006, The European journal of neuroscience.

[43]  C. Nemeroff,et al.  Neurotensin: Role in psychiatric and neurological diseases , 2006, Peptides.

[44]  D. S. Zahm,et al.  Brain neurotensin, psychostimulants, and stress – emphasis on neuroanatomical substrates , 2006, Peptides.

[45]  F. St-Gelais,et al.  The role of neurotensin in central nervous system pathophysiology: what is the evidence? , 2006, Journal of psychiatry & neuroscience : JPN.

[46]  P. Rompré,et al.  Role of Calcium in Neurotensin-Evoked Enhancement in Firing in Mesencephalic Dopamine Neurons , 2004, The Journal of Neuroscience.

[47]  E. Richelson,et al.  Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. , 2003, Life sciences.

[48]  P. Soubrié,et al.  Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia , 2002, Brain Research.

[49]  F. Michel,et al.  Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones , 2002, Neuroscience.

[50]  J. Stamford,et al.  Time window of autoreceptor‐mediated inhibition of limbic and striatal dopamine release , 2002, Synapse.

[51]  C. Nemeroff,et al.  Neurotensin and dopamine interactions. , 2001, Pharmacological reviews.

[52]  V. Pickel,et al.  High‐affinity neurotensin receptors in the rat nucleus accumbens: Subcellular targeting and relation to endogenous ligand , 2001, The Journal of comparative neurology.

[53]  C. Kruse,et al.  Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area , 1999, Neuroscience.

[54]  S. Leeman,et al.  Widespread expression in adult rat forebrain of mRNA encoding high‐affinity neurotensin receptor , 1998, The Journal of comparative neurology.

[55]  A. Beaudet,et al.  Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain , 1998, The Journal of comparative neurology.

[56]  W. Rostène,et al.  Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum. , 1997, Brain research. Molecular brain research.

[57]  A. Beaudet,et al.  Cellular distribution of neurotensin receptors in rat brain: Immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor , 1996, The Journal of comparative neurology.

[58]  P. Soubrié,et al.  SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission , 1994, Neuroscience.

[59]  V. Russell,et al.  Regional effects of neurotensin on the electrically stimulated release of [3H]dopamine and [14C]acetylcholine in the rat nucleus accumbens , 1992, Neurochemical Research.

[60]  B. Bunney,et al.  Roles of intracellular cAMP and protein kinase A in the actions of dopamine and neurotensin on midbrain dopamine neurons , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[61]  K. Fuxe,et al.  Neurotensin Decreases the Affinity of Dopamine D2 Agonist Binding by a G Protein‐Independent Mechanism , 1991, Journal of neurochemistry.

[62]  J. Leysen,et al.  Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain. , 1989, Journal of chemical neuroanatomy.

[63]  P. Kalivas,et al.  Autoradiographic localization of μ-opioid and neurotensin receptors within the mesolimbic dopamine system , 1989, Brain Research.

[64]  R. Quirion,et al.  Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals , 1985, Brain Research.

[65]  P. Kalivas,et al.  Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing , 1984, Neuroscience.

[66]  J. Palacios,et al.  Neurotensin receptors are located on dopamine-containing neurones in rat midbrain , 1981, Nature.

[67]  P. Mallorga,et al.  The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. , 2002, The Journal of pharmacology and experimental therapeutics.